Search results for "sant"

showing 10 items of 2727 documents

Synthesis of 3-Oxa-guaianolides from Santonin

2000

Abstract This article reports on the transformation of santonin into two C10-epimeric 3-oxa-guaianolides which are 8-deoxyderivatives of several natural 3-oxaguaianolides isolated from Achillea species. The synthesis involved the photochemical rearrangement of the eudesmane skeleton into a guaiane skeleton and the transformation of the cyclopentane ring into a furan moiety with the concomitant loss of C3. Comparison of the NMR data of the synthetic products with those of the natural products confirms the β orientation of the hydroxyl group at C10 in the products isolated from Achillea.

AchilleabiologyStereochemistryOrganic Chemistrybiology.organism_classificationRing (chemistry)BiochemistryNmr datachemistry.chemical_compoundchemistryFuranDrug DiscoveryOrganic chemistryMoietyCyclopentaneSantoninTetrahedron
researchProduct

THE REFERENCE SITE COLLABORATIVE NETWORK OF THE EUROPEAN INNOVATION PARTNERSHIP ON ACTIVE AND HEALTHY AGEING

2019

International audience; Seventy four Reference Sites of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) have been recognised by the European Commission in 2016 for their commitment to excellence in investing and scaling up innovative solutions for active and healthy ageing. The Reference Site Collaborative Network (RSCN) brings together the EIP on AHA Reference Sites awarded by the European Commission, and Candidate Reference Sites into a single forum. The overarching goals are to promote cooperation, share and transfer good practice and solutions in the development and scaling up of health and care strategies, policies and service delivery models, while at the…

Active and healthy ageing; DG CONNECT; DG Santé; EIP on AHA; European Innovation Partnership on Active and Healthy AgeingAllergic RhinitisOperational DefinitionEIP on AHAProgramTurkeyActive and healthy ageing; European Innovation Partnership on Active and Healthy Ageing; EIP on AHA; DG CONNECT; DG Sante[SDV]Life Sciences [q-bio]EipActive and healthy ageingDG SanteDG CONNECTDiseasesArticles03 medical and health sciences0302 clinical medicineEuropean Innovation Partnership on Active and Healthy AgeingSynergies030228 respiratory systemDG SantéAhaSettore MED/42030212 general & internal medicineComputingMilieux_MISCELLANEOUS
researchProduct

Acute effects of fluoxetine on inhibitory avoidance consolidation in male and female OF1 mice

2001

The effects of acute administration of fluoxetine on memory consolidation using an inhibitory avoidance task were investigated in male and female OF1 mice. Several doses of this antidepressant (5, 10, and 20 mg/kg) were intraperitoneally administered immediately after the training session. The test session was carried out four days later and response latencies were measured in both sessions. The results showed that the highest dose of fluoxetine significantly increased response latencies of inhibitory avoidance compared with the lowest dose and the control group. Sex differences in this task were observed, females showing a better performance. But the drug's effects were not sexually dimorp…

Acute effectsFluoxetineGeneral NeurosciencePhysiologyInhibitory postsynaptic potentialLocomotor activitySexual dimorphismAvoidance learningAnesthesiamedicineAntidepressantMemory consolidationPsychologymedicine.drugNeuroscience Research Communications
researchProduct

Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRI…

2022

Objective: Post-stroke epilepsy (PSE) is one of the most common causes of acquired epilepsy and accounts for about 10-15% of all newly diagnosed epilepsy cases. However, evidence about the clinical profile of antiseizure medications in the PSE setting is currently limited. Brivaracetam (BRV) is a rationally developed compound characterized by high-affinity binding to synaptic vesicle protein 2A. The aim of this study was to assess the 12-month effectiveness and tolerability of adjunctive BRV in patients with PSE treated in a real-world setting. Methods: This was a subgroup analysis of patients with PSE included in the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). The BRIVAFI…

AdultAntiseizure medication; Brivaracetam; Cerebrovascular diseases; Focal seizures; StrokeCerebrovascular diseasesSettore MED/26Antiseizure medication Brivaracetam Focal seizures Stroke Cerebrovascular diseasesFocal seizuresDouble-Blind MethodDrug TherapySeizuresHumansAgedRetrospective StudiesAntiseizure medicationEpilepsyGeneral MedicineMiddle AgedPyrrolidinonesStrokeTreatment OutcomeNeurologyItalyCombinationBrivaracetamAntiseizure medication; Brivaracetam; Cerebrovascular diseases; Focal seizures; Stroke; Adult; Aged; Anticonvulsants; Double-Blind Method; Drug Therapy Combination; Humans; Italy; Middle Aged; Pyrrolidinones; Retrospective Studies; Seizures; Treatment Outcome; Epilepsy; StrokeDrug Therapy CombinationAnticonvulsantsNeurology (clinical)
researchProduct

How do age and social environment affect the dynamics of death hazard and survival in patients with breast or gynecological cancer in France?

2021

Several studies have investigated the association between net survival and social inequalities in people with cancer, highlighting a varying influence of deprivation depending on the type of cancer studied. However, few of these studies have accounted for the effect of social inequalities over the follow-up period, and/or according to the age of the patients. Thus, using recent and more relevant statistical models, we investigated the effect of social environment on net survival in women with breast or gynecological cancer in France. The data were derived from population-based cancer registries, and women diagnosed with breast or gynecological cancer between 2006 and 2009 were included. We …

AdultCancer ResearchDeprivationGenital Neoplasms FemalePopulationBreast NeoplasmsAffect (psychology)03 medical and health sciencesNet survival0302 clinical medicineBreast cancerBreast cancerMedicineHumansSocial inequality030212 general & internal medicineRegistrieseducationAgedCervical cancerAged 80 and overeducation.field_of_studybusiness.industryAge FactorsSocial environmentCancerMiddle Agedmedicine.diseasePrognosis3. Good healthSurvival RateSocial environmentOncologySocioeconomic Factors030220 oncology & carcinogenesisGynecological cancerFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieFrancebusinessOvarian cancerDemographyFollow-Up Studies
researchProduct

Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures

2022

The maintenance of seizure control over time is a clinical priority in patients with epilepsy. The aim of this study was to assess the sustained seizure frequency reduction with adjunctive brivaracetam (BRV) in real-world practice. Patients with focal epilepsy prescribed add-on BRV were identified. Study outcomes included sustained seizure freedom and sustained seizure response, defined as a 100% and a ≥50% reduction in baseline seizure frequency that continued without interruption and without BRV withdrawal through the 12-month follow-up. Nine hundred ninety-four patients with a median age of 45 (interquartile range = 32-56) years were included. During the 1-year study period, sustained se…

AdultFreedomfocal seizuresEpilepsiesSettore MED/26Double-Blind MethodDrug Therapyantiseizure medication; brivaracetam; focal seizures; seizure freedom; sodium channel blockers; Adult; Double-Blind Method; Drug Therapy Combination; Freedom; Humans; Middle Aged; Pyrrolidinones; Seizures; Treatment Outcome; Anticonvulsants; Epilepsies PartialSeizuresseizure freedomHumansanti-seizure medication; focal seizures; epilepsyantiseizure medicationbrivaracetamanti-seizure medicationMiddle AgedPyrrolidinonesTreatment OutcomeNeurologysodium channel blockersCombinationepilepsyDrug Therapy CombinationAnticonvulsantsNeurology (clinical)Epilepsies PartialPartial
researchProduct

Non-adherence to psychotropic medication assessed by plasma level in newly admitted psychiatric patients: Prevalence before acute admission.

2019

Aims Non-adherence or partial adherence to psychotropic medication is found in 18-70% of patients. Many previously used methods for the assessment of adherence (e.g. questionnaires, pill counts, and electronic systems), however, might underreport actual rates of non-adherence to medication. The aim of this study was to quantify adherence using plasma level. Methods We conducted a 6-week prospective study of all consecutive admitted patients at the Paracelsus Medical University of Salzburg, Clinics of Psychiatry and Psychotherapy, who had been treated with antipsychotics/antidepressants prior to admission (pre-medication dosage in 161 of 233). Plasma drug levels were determined and compared …

AdultHospitals PsychiatricMalemedicine.medical_specialtymedicine.medical_treatmentMedication Adherence03 medical and health sciences0302 clinical medicinePharmacotherapyPatient AdmissionPrevalenceMedicineHumansDosingProspective StudiesAntipsychoticProspective cohort studyPsychiatrymedicine.diagnostic_testbusiness.industryMood DisordersGeneral NeuroscienceMental DisordersGeneral MedicineMiddle Agedmedicine.diseaseAntidepressive Agents030227 psychiatryPsychiatry and Mental healthNeurologyTherapeutic drug monitoringSchizophreniaPillSchizophreniaAntidepressantFemaleNeurology (clinical)business030217 neurology & neurosurgeryAntipsychotic AgentsPsychiatry and clinical neurosciences
researchProduct

Cortisol levels and seizures in adults with epilepsy: A systematic review

2018

Stress has been suggested as a trigger factor for seizures in epilepsy patients, but little is known about cortisol levels, as indicators of stress, in adults with epilepsy. This systematic review summarizes the evidence on this topic. Following PRISMA guidelines, 38 articles were selected: 14 analyzing basal cortisol levels, eight examining antiepileptic drugs (AEDs) effects, 13 focused on seizure effects, and three examining stress. Higher basal cortisol levels were found in patients than in healthy people in studies with the most homogeneous samples (45% of 38 total studies). Despite heterogeneous results associated with AEDs, seizures were related to increases in cortisol levels in 77% …

AdultHypothalamo-Hypophyseal SystemEpilepsyHydrocortisonebusiness.industryCognitive NeurosciencePhysiologymedicine.diseaseBehavioral NeuroscienceEpilepsyFunctional brainBasal (phylogenetics)Neuropsychology and Physiological Psychologymedicine.anatomical_structureSeizuresHomogeneousmedicineHumansAnticonvulsantsChronic stressAcute stressbusinessCortisol levelStress PsychologicalHypothalamic–pituitary–adrenal axisNeuroscience & Biobehavioral Reviews
researchProduct

Do neurologists agree in diagnosing drug resistance in adults with focal epilepsy?

2019

Objective: To evaluate interrater agreement in categorizing treatment outcomes and drug responsiveness status according to the International League Against Epilepsy (ILAE) definition of drug-resistant epilepsy. Methods: A total of 1053 adults with focal epilepsy considered by the investigators to meet ILAE criteria for drug resistance were enrolled consecutively at 43 centers and followed up prospectively for 18-34 months. Treatment outcomes for all antiepileptic drugs (AEDs) used up to enrollment (retrospective assessment), and on an AED newly introduced at enrollment, were categorized by individual investigators and by 2 rotating members of a 16-member expert panel (EP) that reviewed the …

AdultMale0301 basic medicineDrug Resistant Epilepsymedicine.medical_specialtyPediatricsNeurologyAttitude of Health PersonnelTreatment outcomeantiepileptic drugs; classification; drug-resistant epilepsy; epilepsy; ILAE definition; reliability; Neurology; Neurology (clinical)Drug resistance03 medical and health sciencesEpilepsyantiepileptic drug0302 clinical medicinedrug-resistant epilepsymedicineHumansNeurologistsProspective Studiesantiepileptic drugsCooperative Behaviorreliabilitybusiness.industryMiddle Agedmedicine.diseaseDrug Resistant EpilepsyConfidence intervalInter-rater reliability030104 developmental biologyclassificationNeurologyepilepsyAnticonvulsantsFemaleEpilepsies PartialNeurology (clinical)businessILAE definition030217 neurology & neurosurgeryKappa
researchProduct

Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell's palsy

2021

Therapies - Sous presse. Epreuves corrigees par l'auteur. Disponible en ligne depuis le mardi 13 avril 2021

AdultMale2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)COVID-19 vaccines030226 pharmacology & pharmacyArticle03 medical and health sciencesPharmacovigilance0302 clinical medicineBell's palsyPhase 3 clinical trialsBell PalsymedicineType I interferonsHumansBell's palsyPharmacology (medical)Potential mechanismComputingMilieux_MISCELLANEOUSAgedCOVID-19 coronavirus disease 2019Vaccines SyntheticMessenger RNASARS-CoV-2business.industryCOVID-19Bell’s palsyMiddle Agedmedicine.diseaseVirologymRNA messenger RNA3. Good healthInterferon Type IFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusiness
researchProduct